Feasibility, Acceptability, and Safety of Faecal Microbiota Transplantation in the Treatment of Major Depressive Disorder: A Pilot Randomized Controlled Trial.

FMT MDD depression faecal microbiota transplantation major depressive disorder mental disorder mental health microbiome mood disorders psychiatry

Journal

Canadian journal of psychiatry. Revue canadienne de psychiatrie
ISSN: 1497-0015
Titre abrégé: Can J Psychiatry
Pays: United States
ID NLM: 7904187

Informations de publication

Date de publication:
05 2023
Historique:
medline: 18 5 2023
pubmed: 14 1 2023
entrez: 13 1 2023
Statut: ppublish

Résumé

Perturbations of the intestinal microbiota have been associated with mental health disorders, including major depressive disorder (MDD). Therefore, faecal microbiota transplantation (FMT) holds promise as a microbiota-modulating treatment for MDD. Yet, to date, there are no published controlled studies evaluating the use of FMT for MDD. This study aimed to address this gap by evaluating the feasibility, acceptability, and safety of FMT for MDD. The study was an 8-week, double-blind, 2:1 parallel group, randomized controlled pilot trial ( Recruitment was completed within 2 months, with 0% attrition and 100% attendance at key study appointments. There were no major protocol deviations. The placebo and blinding strategies were considered successful; nurses and participants correctly guessing their treatment allocation at a rate similar to that anticipated by chance. No serious or severe adverse events were reported in either group, and there were no significant differences in mild-to-moderate adverse events between groups (median of 2 adverse events per participant reported in both groups). Furthermore, the 12/15 participants who completed the Week 2 participant satisfaction survey agreed or strongly agreed that the enema delivery was tolerable and that they would have the treatment again if required. Whilst the study was not designed to measure clinical outcomes, exploratory data also suggested that the active FMT treatment may lead to improvements in gastrointestinal symptoms and quality of life in this population, noting that irritable bowel syndrome is commonly comorbid with MDD. All feasibility targets were met or exceeded. This study found that enema-delivered FMT is feasible, acceptable, well-tolerated, and safe in patients with MDD. The findings of this study support further research to evaluate clinical efficacy, and the use of this protocol is supported.

Identifiants

pubmed: 36637229
doi: 10.1177/07067437221150508
pmc: PMC10192831
doi:

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

315-326

Références

BMC Med. 2013 May 15;11:129
pubmed: 23672628
Cien Saude Colet. 2021 Sep;26(9):4087-4099
pubmed: 34586262
Aust N Z J Psychiatry. 2020 Jun;54(6):649-650
pubmed: 32228039
J Psychosom Res. 2002 Sep;53(3):737-40
pubmed: 12217446
Bipolar Disord. 2022 Aug;24(5):559-563
pubmed: 35165993
Neurogastroenterol Motil. 2022 Aug;34(8):e14320
pubmed: 35037353
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
Neuropsychiatr Dis Treat. 2020 Mar 31;16:859-869
pubmed: 32280227
Eur Psychiatry. 2018 Sep;53:17-22
pubmed: 29859377
J Clin Psychiatry. 1995 Aug;56(8):363-7
pubmed: 7635853
Can J Psychiatry. 2010 Mar;55(3):126-35
pubmed: 20370962
Qual Life Res. 1999 May;8(3):209-24
pubmed: 10472152
Gut Microbes. 2020 Nov 9;12(1):1-25
pubmed: 33345703
Health Qual Life Outcomes. 2020 Oct 1;18(1):321
pubmed: 33004068
Biol Psychiatry. 2015 Apr 1;77(7):607-15
pubmed: 25173628
Curr Opin Psychiatry. 2015 Jan;28(1):1-6
pubmed: 25415497
BMC Med. 2017 Jan 30;15(1):23
pubmed: 28137247
World J Clin Cases. 2019 Oct 6;7(19):3074-3081
pubmed: 31624757
Acta Neuropsychiatr. 2007 Oct;19(5):304-10
pubmed: 26952943
Front Psychiatry. 2022 Feb 17;13:815422
pubmed: 35250668
J Psychiatr Res. 2016 Nov;82:109-18
pubmed: 27491067
Microbiome. 2017 Jan 23;5(1):10
pubmed: 28122648
J Neurogastroenterol Motil. 2022 Jan 30;28(1):28-42
pubmed: 34980687
Neurosci Biobehav Rev. 2019 Jul;102:13-23
pubmed: 31004628
Qual Life Res. 1998 Jan;7(1):75-83
pubmed: 9481153
Mol Psychiatry. 2016 Jun;21(6):786-96
pubmed: 27067014
Gut. 2020 May;69(5):859-867
pubmed: 31852769
Mol Psychiatry. 2013 Jun;18(6):666-73
pubmed: 22688187
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
J Proteomics. 2019 Mar 1;194:132-147
pubmed: 30521978
Bipolar Disord. 2021 Nov;23(7):651-655
pubmed: 34841639
JAMA Psychiatry. 2019 Mar 1;76(3):271-279
pubmed: 30516814
PLoS One. 2020 Jan 15;15(1):e0226128
pubmed: 31940312
World J Gastroenterol. 2015 Oct 14;21(38):10907-14
pubmed: 26478682
Int Clin Psychopharmacol. 2008 Mar;23(2):70-83
pubmed: 18301121
Mol Psychiatry. 2022 Apr;27(4):1920-1935
pubmed: 35194166
Actas Esp Psiquiatr. 2020 Jan;48(1):1-7
pubmed: 32297646
Psychiatry Clin Neurosci. 2019 Dec;73(12):754-760
pubmed: 31490607
Int Psychogeriatr. 2019 Oct;31(10):1525-1526
pubmed: 30782238
Aust N Z J Psychiatry. 2019 Aug;53(8):732-734
pubmed: 30957511
Indian J Gastroenterol. 2018 Jul;37(4):307-312
pubmed: 30196516
J Mol Psychiatry. 2014 Jun 27;2(1):4
pubmed: 25408914
Sci Adv. 2019 Feb 06;5(2):eaau8317
pubmed: 30775438
Psychoneuroendocrinology. 2014 Apr;42:207-17
pubmed: 24636517
Gastroenterology. 2011 Aug;141(2):599-609, 609.e1-3
pubmed: 21683077
Physiol Rev. 2019 Oct 1;99(4):1877-2013
pubmed: 31460832
Nat Microbiol. 2019 Mar;4(3):396-403
pubmed: 30531975
Clin Epidemiol. 2018 Jan 18;10:153-157
pubmed: 29403314
Acta Psychiatr Scand. 1986 May;73(5):544-8
pubmed: 3751660
J Dig Dis. 2019 Aug;20(8):401-408
pubmed: 31070838
J Affect Disord. 2018 Aug 1;235:506-512
pubmed: 29684865
Bipolar Disord. 2018 Nov;20(7):614-621
pubmed: 29693757
Nat Commun. 2017 Apr 04;8:15062
pubmed: 28375200
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3047-52
pubmed: 21282636
Ann Gastroenterol. 2021 Nov-Dec;34(6):802-814
pubmed: 34815646

Auteurs

Jessica Emily Green (JE)

Deakin University, Food & Mood Centre, IMPACT (the Institute for Mental and Physical Health and Clinical Translation, Geelong, Victoria, Australia.
Monash Alfred Psychiatry Research Centre (MAPrc), Central Clinical School, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia.
Department of Psychiatry, Peninsula Health, Frankston, Australia.

Michael Berk (M)

Deakin University, Food & Mood Centre, IMPACT (the Institute for Mental and Physical Health and Clinical Translation, Geelong, Victoria, Australia.
Department of Psychiatry, University of Melbourne, Parkville, Australia.

Mohammadreza Mohebbi (M)

Deakin University, Food & Mood Centre, IMPACT (the Institute for Mental and Physical Health and Clinical Translation, Geelong, Victoria, Australia.
Faculty of Health, Biostatistics Unit, Deakin University, Geelong, Australia.

Amy Loughman (A)

Deakin University, Food & Mood Centre, IMPACT (the Institute for Mental and Physical Health and Clinical Translation, Geelong, Victoria, Australia.

Amelia J McGuinness (AJ)

Deakin University, Food & Mood Centre, IMPACT (the Institute for Mental and Physical Health and Clinical Translation, Geelong, Victoria, Australia.

David Castle (D)

Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Parkville, Australia.

Mary Lou Chatterton (ML)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Institute for Health Transformation, Deakin University, Geelong, Australia.

Joahna Perez (J)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Philip Strandwitz (P)

Holobiome, Boston, MA, USA.

Eugene Athan (E)

Deakin University, Food & Mood Centre, IMPACT (the Institute for Mental and Physical Health and Clinical Translation, Geelong, Victoria, Australia.
School of Medicine, Barwon Health, Geelong, Australia.
School of Medicine, Deakin University, Geelong, Australia.

Christopher Hair (C)

School of Medicine, Barwon Health, Geelong, Australia.

Andrew A Nierenberg (AA)

Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

John F Cryan (JF)

Department of Anatomy and Neuroscience, University College Cork and APC Microbiome, County Cork, Ireland.

Felice Jacka (F)

Deakin University, Food & Mood Centre, IMPACT (the Institute for Mental and Physical Health and Clinical Translation, Geelong, Victoria, Australia.
Centre for Adolescent Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia.
College of Public Health, Medical & Veterinary Sciences, James Cook University, Townsville, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH